AstraZeneca, Ironwood score PhIII success in China

AstraZeneca ($AZN) and Ironwood Pharmaceuticals ($IRWD) say their Phase III study for linaclotide, conducted primarily in China among patients with irritable bowel syndrome with constipation, came through on all primary and secondary endpoints. The successful late-stage study sets the stage for a regulatory filing in China next year as the developers target a market of some 13 million patients. The drug is already approved in the U.S. Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.